Cargando…

Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission

We investigated the characteristics of neovascular age-related macular degeneration (AMD), which rarely recurs after initial remission. This study retrospectively analyzed 392 neovascular AMD patients treated with anti-vascular endothelial growth factor (VEGF). All patients received three monthly lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Han Joo, Jeon, Young Joon, Yoon, Wontae, Yoon, Jihyun, Kim, Jaemin, Kim, Jong Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485132/ https://www.ncbi.nlm.nih.gov/pubmed/36123375 http://dx.doi.org/10.1038/s41598-022-19400-4

Ejemplares similares

Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor treatment
por: Cho, Han Joo, et al.
Publicado: (2022)

Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization
por: Yoon, Wontae, et al.
Publicado: (2021)

Non-Neovascular Pachychoroid Disease Mimicking Exudative Age-Related Macular Degeneration
por: Kaseewat, Thachpacha, et al.
Publicado: (2021)

The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration
por: Inan, Sibel, et al.
Publicado: (2019)

Real-world study to evaluate the efficacy and safety of intravitreal brolucizumab for refractory neovascular age-related macular degeneration
por: Yeom, Hoseok, et al.
Publicado: (2023)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

The Diagnostic Capability of Swept Source OCT Angiography in Treatment-Naive Exudative Neovascular Age-Related Macular Degeneration
por: Ahmed, Daniel, et al.
Publicado: (2021)

Quantitative optical coherence tomography angiography biomarkers for neovascular age-related macular degeneration in remission
por: Coscas, Florence, et al.
Publicado: (2018)

Subthreshold Exudative Choroidal Neovascularization (CNV): Presentation of This Uncommon Subtype and Other CNVs in Age-Related Macular Degeneration (AMD)
por: Douglas, Vivian Paraskevi, et al.
Publicado: (2022)

Morphology of en face Haller vessel and macular neovascularization at baseline and 3 months as predictive factors in age-related macular degeneration
por: Lee, Hyungwoo, et al.
Publicado: (2022)

Association of neovascular age-related macular degeneration with month and season of birth in Italy
por: Longo, Antonio, et al.
Publicado: (2016)

Therapeutic Modalities of Exudative Age-related Macular Degeneration
por: Mavija, Milka, et al.
Publicado: (2014)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

Correlation of the OCT Double-Layer Sign with Type 1 Non-Exudative Neovascularization on OCT-A in Age-Related Macular Degeneration
por: Ristic, Dragana, et al.
Publicado: (2023)

Outer nuclear layer recovery as a predictor of visual prognosis in type 1 choroidal neovascularization of neovascular age-related macular degeneration
por: Lee, Seungheon, et al.
Publicado: (2023)

Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes
por: Figurska, Małgorzata, et al.
Publicado: (2011)

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol
por: Lin, Tiezhu, et al.
Publicado: (2020)

Is monthly retreatment with intravitreal bevacizumab (Avastin(®)) necessary in neovascular age-related macular degeneration?
por: Ghazi, Nicola G, et al.
Publicado: (2010)

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study
por: Rakic, Jean-Marie, et al.
Publicado: (2013)

Early Signs of Exudative Age-Related Macular Degeneration in Asians
por: Sasaki, Mariko, et al.
Publicado: (2014)

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Unusual visual loss in a patient with exudative macular degeneration
por: Peng, Enoch T., et al.
Publicado: (2022)

Relationship between Neovascular Density in Swept Source-Optical Coherence Tomography Angiography and Signs of Activity in Exudative Age-Related Macular Degeneration
por: Stattin, Martin, et al.
Publicado: (2019)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

THE RAP STUDY, REPORT 5: REDISCOVERING MACULAR NEOVASCULARIZATION TYPE 3: Multimodal Imaging of Fellow Eyes over 24 months
por: Haj Najeeb, Bilal, et al.
Publicado: (2022)

Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration
por: Kikushima, Wataru, et al.
Publicado: (2017)

Use of nepafenac (Nevanac(®)) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections
por: Chen, Eric, et al.
Publicado: (2010)

Comparison of 24-month treatment outcomes between as-needed treatment and switching to treat-and-extend in type 3 macular neovascularization
por: Kim, Jae Hui, et al.
Publicado: (2022)

Optical Coherence Tomography-Based Deep-Learning Models for Classifying Normal and Age-Related Macular Degeneration and Exudative and Non-Exudative Age-Related Macular Degeneration Changes
por: Motozawa, Naohiro, et al.
Publicado: (2019)

Title: efficacy of intravitreal dexamethasone implant on hard exudate in diabetic macular edema
por: Yoon, Chang Ki, et al.
Publicado: (2021)

Anti-VEGF-refractory Exudative Age-related Macular Degeneration: Differential Response According to Features on Optical Coherence Tomography
por: Shin, Joo Young, et al.
Publicado: (2013)

Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up
por: Matsumiya, Wataru, et al.
Publicado: (2013)

The Effect of Treatment Discontinuation During the COVID-19 Pandemic on Visual Acuity in Exudative Neovascular Age-Related Macular Degeneration: 1-Year Results
por: Stattin, Martin, et al.
Publicado: (2021)

The Past, Present, and Future of Exudative Age-Related Macular Degeneration Treatment
por: Barak, Yoreh, et al.
Publicado: (2012)

Proteomics of Vitreous Humor of Patients with Exudative Age-Related Macular Degeneration
por: Koss, Michael Janusz, et al.
Publicado: (2014)

High-Density Lipoprotein Function in Exudative Age-Related Macular Degeneration
por: Pertl, Laura, et al.
Publicado: (2016)

Real-Life Data of Patients with Exudative Age-Related Macular Degeneration
por: Togac, Mesut, et al.
Publicado: (2021)

Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
por: Schmucker, Christine M., et al.
Publicado: (2015)

Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
por: Hariprasad, Seenu M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mravuk9p5jdv3upku1n19lkihc